Patient demographics and outcomes
| Patient study number . | Sex (M/F) . | Ethnicity . | Age . | Type of cancer . | Active disease sites . | Stage . | Number of TCR transgenic cells . | IL2 doses . | DC doses . | Evidence of transient tumor response . | Response at EOS (day 90) . | PFS (mo) . | OS (mo) . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F5-1 | M | Caucasian | 60 | Melanoma | Lung, stomach, liver, pancreas, peritoneum, soft tissues | M1c | 1 × 109 | 12/14 | 3/3 | Yes by PET/CT | PD | 3 | 5 | Died of disease |
| F5-3 | M | Caucasian | 61 | Melanoma | Lung, liver | M1c | 1 × 109 | 13/14 | 3/3 | Yes by PET/CT | SD | 7 | 86 | Died of disease |
| F5-6 | M | Caucasian | 59 | Melanoma | Lung, LN | M1b | 1 × 109 | 13/14 | 3/3 | Yes by PE | SD | 3 | 4 | Died of disease |
| F5-7 | M | Caucasian | 48 | Melanoma | SC, bone | M1c | 1 × 109 | 9/14 | 3/3 | Yes by CT | SD | 4 | 11 | Died of disease |
| F5-8 | M | Caucasian | 44 | Melanoma | LN, liver | M1c | 1 × 109 | 11/14 | 3/3 | Yes by PET/CT | SD | 4 | 11 | Died of disease |
| F5-9 | F | Caucasian | 46 | Melanoma | Skin, LN | M1a | 1 × 109 | 11/14 | 3/3 | No | PD | 3 | 20 | Died of disease |
| F5-12 | M | Caucasian | 40 | Melanoma | Lung, LN | MIVb | 3.9 × 109 | 6/9 | 3/3 | Yes by PET/CT | SD | 5 | 8 | Died of disease |
| F5-13 | M | Caucasian | 60 | Melanoma | Lung, abdomen, SC | MIIIb | 4.41 × 109 | 4/9 | 3/3 | Yes by PET/CT | SD | 3 | 8 | Died of disease |
| ESO-1 | M | Hispanic | 47 | Liposarcoma | Right renal fossa; liver left lobe; hepatic segment; peritoneal, perihepatic nodule | IV | 7.7 × 108 | 28/28 | 3/3 | No | PD | 2.6 | 16 | Died of disease |
| ESO-3 | F | Caucasian | 24 | Synovial sarcoma | Right lung; multiple pulmonary nodules | IV | 1 × 109 | 19/28 | 1/3 | Yes by PET/CT | PR | 67 | 67 | Alive with CR |
| ESO-4 | M | Caucasian | 41 | Synovial sarcoma | Left infraclavicular mass; left pectoralis mass | III | 1 × 109 | 18/28 | 3/3 | Yes by PET/CT | PD | 3 | 25 | Died of disease |
| ESO-5 | F | Caucasian | 43 | Synovial sarcoma | Right popliteal fossa; lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PR | 9 | 41.5 | Died of disease |
| ESO-6 | M | Caucasian | 26 | Osteosarcoma | Lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 2.5 | 19 | Died of disease |
| INY-2 | M | Caucasian | 66 | Melanoma | LN, liver | IV | 1 × 109 | 21/28 | 2/3 | Yes by PET/CT | PD | 3 | 6 | Died of disease |
| INY-3 | F | Caucasian | 44 | Synovial sarcoma | Right popliteal fossa; lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 3 | 31 | Died of disease |
| INY-4 | M | Hispanic | 24 | Melanoma | Lung, LN, adrenal gland, liver, trachea, brain | IV | 1 × 109 | 10/14 | 3/3 | No | PD | NA | 3 | Died of disease |
| Patient study number . | Sex (M/F) . | Ethnicity . | Age . | Type of cancer . | Active disease sites . | Stage . | Number of TCR transgenic cells . | IL2 doses . | DC doses . | Evidence of transient tumor response . | Response at EOS (day 90) . | PFS (mo) . | OS (mo) . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F5-1 | M | Caucasian | 60 | Melanoma | Lung, stomach, liver, pancreas, peritoneum, soft tissues | M1c | 1 × 109 | 12/14 | 3/3 | Yes by PET/CT | PD | 3 | 5 | Died of disease |
| F5-3 | M | Caucasian | 61 | Melanoma | Lung, liver | M1c | 1 × 109 | 13/14 | 3/3 | Yes by PET/CT | SD | 7 | 86 | Died of disease |
| F5-6 | M | Caucasian | 59 | Melanoma | Lung, LN | M1b | 1 × 109 | 13/14 | 3/3 | Yes by PE | SD | 3 | 4 | Died of disease |
| F5-7 | M | Caucasian | 48 | Melanoma | SC, bone | M1c | 1 × 109 | 9/14 | 3/3 | Yes by CT | SD | 4 | 11 | Died of disease |
| F5-8 | M | Caucasian | 44 | Melanoma | LN, liver | M1c | 1 × 109 | 11/14 | 3/3 | Yes by PET/CT | SD | 4 | 11 | Died of disease |
| F5-9 | F | Caucasian | 46 | Melanoma | Skin, LN | M1a | 1 × 109 | 11/14 | 3/3 | No | PD | 3 | 20 | Died of disease |
| F5-12 | M | Caucasian | 40 | Melanoma | Lung, LN | MIVb | 3.9 × 109 | 6/9 | 3/3 | Yes by PET/CT | SD | 5 | 8 | Died of disease |
| F5-13 | M | Caucasian | 60 | Melanoma | Lung, abdomen, SC | MIIIb | 4.41 × 109 | 4/9 | 3/3 | Yes by PET/CT | SD | 3 | 8 | Died of disease |
| ESO-1 | M | Hispanic | 47 | Liposarcoma | Right renal fossa; liver left lobe; hepatic segment; peritoneal, perihepatic nodule | IV | 7.7 × 108 | 28/28 | 3/3 | No | PD | 2.6 | 16 | Died of disease |
| ESO-3 | F | Caucasian | 24 | Synovial sarcoma | Right lung; multiple pulmonary nodules | IV | 1 × 109 | 19/28 | 1/3 | Yes by PET/CT | PR | 67 | 67 | Alive with CR |
| ESO-4 | M | Caucasian | 41 | Synovial sarcoma | Left infraclavicular mass; left pectoralis mass | III | 1 × 109 | 18/28 | 3/3 | Yes by PET/CT | PD | 3 | 25 | Died of disease |
| ESO-5 | F | Caucasian | 43 | Synovial sarcoma | Right popliteal fossa; lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PR | 9 | 41.5 | Died of disease |
| ESO-6 | M | Caucasian | 26 | Osteosarcoma | Lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 2.5 | 19 | Died of disease |
| INY-2 | M | Caucasian | 66 | Melanoma | LN, liver | IV | 1 × 109 | 21/28 | 2/3 | Yes by PET/CT | PD | 3 | 6 | Died of disease |
| INY-3 | F | Caucasian | 44 | Synovial sarcoma | Right popliteal fossa; lung | IV | 1 × 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 3 | 31 | Died of disease |
| INY-4 | M | Hispanic | 24 | Melanoma | Lung, LN, adrenal gland, liver, trachea, brain | IV | 1 × 109 | 10/14 | 3/3 | No | PD | NA | 3 | Died of disease |
Abbreviations: CR, complete response; DC, dendritic cells; EOS, end of study; F, female; LN, lymph nodes; M, male; mo, months; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SC, subcutaneous; SD, stable disease.